Assignee
UNITY BIOTECHNOLOGY INC
US·26 granted patents·23 pending applications·62 citations·filing 2013–2024
Top patents by PatentIndex Score
49 records- 0197US10195213B2Chemical entities that kill senescent cells for use in treating age-related diseaseUNITY BIOTECHNOLOGY INC·Filed 2016·Granted Feb 5, 2019·15 cites·8 claims
- 0295US10328073B2Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Jun 25, 2019·9 cites·16 claims
- 0395US10130628B2Treatment of joint painUNITY BIOTECHNOLOGY INC·Filed 2017·Granted Nov 20, 2018·6 cites·8 claims
- 0492US10981892B2Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2020·Granted Apr 20, 2021·2 cites·1 claims
- 0592US10517866B2Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitorUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Dec 31, 2019·5 cites·15 claims
- 0690US10478433B2Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision lossUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Nov 19, 2019·4 cites·20 claims
- 0790US2025188055A1Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 0889US10519197B1Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Dec 31, 2019·3 cites·14 claims
- 0989US10426788B2Chemical entities that kill senescent cells for use in treating age-related diseaseUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Oct 1, 2019·2 cites·8 claims
- 1088US10550378B2Composition comprising a gene vector that selectively depletes P16 positive senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Feb 4, 2020·2 cites·10 claims
- 1188US10378002B2Replication conditional virus that specifically kills senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Aug 13, 2019·2 cites·8 claims
- 1286US11129838B2Methods of inhibiting pathological angiogenesisUNITY BIOTECHNOLOGY INC·Filed 2020·Granted Sep 28, 2021·2 cites·28 claims
- 1386US10717722B2Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jul 21, 2020·2 cites·9 claims
- 1486US10279018B2Immunogenic compositions for inducing an immune response for elimination of senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2013·Granted May 7, 2019·3 cites·14 claims
- 1584US10588916B2Technology to inhibit vascular changes that lead to vision loss in the eyeUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Mar 17, 2020·2 cites·5 claims
- 1679US2019343832A1Therapy for removing senescent cells and treating senescence-associated disease using an mdm2 inhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 1778US12221433B2Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2021·Granted Feb 11, 2025·0 cites·1 claims
- 1877US12195542B2Antibodies directed to Tie-2 and methods of useUNITY BIOTECHNOLOGY INC·Filed 2020·Granted Jan 14, 2025·1 cites·18 claims
- 1973US2020370029A1Composition comprising a gene vector that selectively depletes p16 positive senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 2072US9988368B1Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical useUNITY BIOTECHNOLOGY INC·Filed 2017·Granted Jun 5, 2018·1 cites·19 claims
- 2171US9969776B2Drug conjugates for delivering compounds to senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2016·Granted May 15, 2018·1 cites·18 claims
- 2271US2020069703A1Chemical entities that kill senescent cells for use in treating age-related diseaseUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 2370US11865123B2Methods of inhibiting pathological angiogenesisUNITY BIOTECHNOLOGY INC·Filed 2021·Granted Jan 9, 2024·0 cites·6 claims
- 2469US2020338094A1Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 2568US10745429B2Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Aug 18, 2020·0 cites·15 claims
- 2667US2018000816A1Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 2764US10689416B2Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jun 23, 2020·0 cites·10 claims
- 2863US2024342202A1Methods of Treating Retinal VasculopathiesUNITY BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 2962US2019201510A1Passive vaccine for elimination of senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 3061US11951115B2Methods of treating retinal vasculopathiesUNITY BIOTECHNOLOGY INC·Filed 2022·Granted Apr 9, 2024·0 cites·33 claims
- 3161US2020392105A1Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3261US2020399259A1Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3361US2024392012A1Antibodies Directed to TIE-2 and Methods of UseUNITY BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 3460US2020354336A9Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent CellsUNITY BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 3560US2025250343A1Antibodies Directed To Tie-2 and VEGF and Methods of UseUNITY BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 3659US10745445B2Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Aug 18, 2020·0 cites·14 claims
- 3759US2021070788A1Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating CancerUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3858US2020338097A1Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditionsUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 3956US10329279B2Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical useUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Jun 25, 2019·0 cites·18 claims
- 4055US2019270726A1Products of chiral synthesis of cis-imidazoline compounds and their useUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 4153US2024043456A1Crystalline Solid Meglumine Salt Inhibitor of BCL and Methods of Making and Using SameUNITY BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 4252US2016017033A1Compositions and methods for detecting or eliminating senescent cells to diagnose or treat diseaseUNITY BIOTECHNOLOGY INC·Filed 2015·Application pending·0 cites
- 4351US2018193458A1Compositions and methods for treating senescence-associated diseases and disordersUNITY BIOTECHNOLOGY INC·Filed 2016·Application pending·0 cites
- 4450US2016166718A1Compositions and methods for detecting or eliminating senescent cells to diagnose or treat diseaseUNITY BIOTECHNOLOGY INC·Filed 2016·Application pending·0 cites
- 4548US2017266211A1Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditionsUNITY BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 4646US10703745B2Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancerUNITY BIOTECHNOLOGY INC·Filed 2019·Granted Jul 7, 2020·0 cites·18 claims
- 4746US2020360386A1Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related ConditionsUNITY BIOTECHNOLOGY INC·Filed 2018·Application pending·0 cites
- 4842US2021379078A1Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 InhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 4937US11111259B2Acylsulfonamide derivatives for treating senescence-associated diseases and disordersUNITY BIOTECHNOLOGY INC·Filed 2016·Granted Sep 7, 2021·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when UNITY BIOTECHNOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →